Lucentis as an Adjuvant Therapy With TTT-ICG Based in Choroidal Melanoma

Part of paid clinical trials in Hamden, Connecticut.

Sponsor
New England Retina Associates
Study ID
NCT00680225
Phase
PHASE3
Status
Completed

Conditions

  • Choroidal Melanoma

Eligibility Criteria

Sex
ALL
Age
18 Years - 90 Years
Healthy Volunteers
Accepted

Interventions

  • Ranibizumab injection and TTT - ICG based — DRUG
    Intravitreal injection of ranibizumab (0.5mg) once a month for 6 months and transpupillary thermotherapy enhanced with Indocyanine Green (ICG) dye, once or twice starting at 2nd month.

Study Details

To report preliminary results on safety and tolerability of intravitreal injection of Ranibizumab (Lucentis) combined with Transpupillary Thermotherapy (TTT)+ Indocyanine Green (ICG)-based photodynamic therapy (PDT) in the treatment of choroidal melanoma.

Key Dates

First listed
May 20, 2008
Start date
Sep 30, 2007
Status verified
Apr 2017
Primary completion
Jul 31, 2012
Completion
Jul 31, 2012

Study Design

Enrollment
10 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Lucentis Injection
    Intravitreal injection of ranibizumab (0.5mg) once a month for 6 months and transpupillary thermotherapy enhanced with Indocyanine Green (ICG) dye, once or twice starting at 2nd month.

Primary Outcome Measure

Mean Tumor Thickness [ Time Frame: 12 mo ]

Locations (1)

FacilityCityStateZIPSite coordinators
New England Retina AssociatesHamdenConnecticut06518-

Find similar trials in Hamden, CT

By research site
New England Retina Associates· Hamden, CT

Related Studies